ZM-008 is under clinical development by Zumutor Biologics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZM-008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZM-008 overview
ZM-008 is under development for the treatment of unspecified B cell lymphoma, glioblastoma multiforme, prostate cancer, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer, high grade serious ovarian cancer, diffuse large B-cell lymphoma and urothelial cancer. The drug candidate is administered through intravenous route. The drug candidate acts by targeting lectin like transcript 1.
It was also under development for the treatment of rheumatoid arthritis.
Zumutor Biologics overview
Zumutor Biologics is developing first-in-class therapeutic antibodies which target innate immunity and regulate the tumor microenvironment. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of ZM-008’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.